JNJ: Novel next generation assets

Novel next generation assets

JNJ

We present an update to our September 2020 detailed pipeline analysis “JNJ NME pipeline”, examining the prospects of three new molecular entities and the competitive positioning of two drugs that achieved FDA approval as predicted. We see milvexian, a novel factor XIa inhibitor, with the most potential upside, attempting to reshape the anticoagulation landscape.